Metformin inhibits monocyte adhesion to endothelial cells and foam cell formation

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue 4, 2003, Pages 302-310

  Mamputu, Jean Claude ^a   Wiernsperger, Nicolas ^b   Renier, Geneviève ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b Intl Pharmacological Support   (France)

Author keywords

Adhesion molecules; Advanced glycation end products; Macrophages foam cells; Metformin; Monocyte adhesion

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CELL ADHESION MOLECULE; LOW DENSITY LIPOPROTEIN RECEPTOR; METFORMIN; SCAVENGER RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DRUG MECHANISM; ENDOTHELIUM CELL; FOAM CELL; HUMAN; HUMAN CELL; INCUBATION TIME; LIPID STORAGE; MACROPHAGE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; UNITED KINGDOM; WESTERN BLOTTING;

EID: 0042878553     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514030030041501     Document Type: Article

References (46)

1. Howard BV, Rodriguez BL, Bennett PH et al. Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology. Circulation 2002;105:e132-7.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk for complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
4. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Reviews 1998;6:89-131.
5. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993;16:653-5.
6. Uehara MH, Kohlmann NE, Zanella MT, Ferreira SR. Metabolic and haemodynamic effects of metformin in patients with type 2 diabetes mellitus and hypertension. Diabetes Obes Metab 2001;3:319-25.
7. Chu NV, Kong APS, Kim DD et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002;25:542-9.
8. Grant PJ. The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects. Diabetes Metab 1991;17:168-73.
9. Pavlovic D, Kocic R, Kocic G et al. Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes. Diabetes Obes Metab 2000;2:251-6.
10. Tessier D, Maheux P, Khalil A, Fulop T. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism 1999;48:897-903.
11. Wiernsperger NF. Metformin: intrinsic vasculoprotective properties. Diabetes Technol Ther 2000;2:259-72.
12. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001;37: 1344-50.
13. Carantoni M, Abbasi F, Chu L et al. Adherence of mononuclear cells to endothelium in vitro is increased in patients with NIDDM. Diabetes Care 1997;20:1462-6.
14. Desfaits AC, Serri O, Renier G. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-α production in NIDDM patients after gliclazide treatment. Diabetes Care 1998;21:487-93.
15. Schmidt AM, Hori O, Chen JX et al. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995;96:1395-403.
16. Desfaits AC, Serri O, Renier G. Gliclazide reduces the induction of human monocyte adhesion to endothelial cells by glycated albumin. Diabetes Obes Metab 1999;1:113-20.
17. Kunt T, Forst T, Wilhem A et al. The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. Exp Clin Endocrinol Diabetes 1998;106:183-8.
18. Mentzer SJ, Guyre PM, Burakoff SJ, Faller DV. Spontaneous aggregation as a mechanism for human monocyte purification. Cell Immunol 1986;101:312-19.
19. Bath PMW, Booth RFG, Hassal DG. Monocyte-lymphocyte discrimination in a new microtitre-based adhesion assay. J Immunol Methods 1989;118:59-65.
20. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
22. Vosper H, Patel L, Graham TL et al. The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages. J Biol Chem 2001;276:44258-65.
23. Gough PJ, Greaves DR, Suzuki H et al. Analysis of macrophage scavenger receptor (SR-A) expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999;19:461-71.
24. Yoshida H, Kondratenko N, Green S, Steinberg D, Quehenberger O. Identification of the lectin-like receptor for oxidized low-density lipoprotein in human macrophages and its potential role as a scavenger receptor. Biochem J 1998;334:9-13.
25. Jungi TW, Miserez R, Brcic M, Pfister H. Change in sensitivity to lipopolysaccharide during the differentiation of human monocytes to macrophages in vitro. Experientia 1994;50:110-14.
26. Friedman EA. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care 1999; 22:B65-B71.
27. Singh R, Barden A, Mori T et al. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46.
28. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002;251:87-101.
29. Krieglstein CF, Granger DN. Adhesion molecules and their role in vascular disease. Am J Hypertens 2001;14:44-54.
30. Faruqi RM, Poptic EJ, Faruqi TR, de la Motte C, DiCorleto P. Distinct mechanisms for N-acetylcysteine inhibition of cytokine-induced E-selectin and VCAM-1 expression. Am J Physiol 1997;273:817-26.
31. Detaille D, Guigas B, Leverve X, Wiernsperger N, Devos P. Obligatory role of membrane events in the regulatory effect of metformin on the respiratory chain function. Biochem Pharmacol 2002;63:1259-72.
32. 2+]. J Hypertens 1997;15:269-74.
33. Altieri DC. Occupancy of CD11b/CD18 (Mac-1) divalent ion binding site (s) induces leukocyte adhesion. J Immunol 1991;147:1891-8.
34. Pawlowski NA, Abraham EL, Pontier S, Scott WA, Cohn ZA. Human monocyte-endothelial cell interaction in vitro. Proc Natl Acad Sci 1985;82:8208-12.
35. Omi H, Okayama N, Shimuzu M et al. Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells. Effect of antidiabetic medicines. J Diabetes Complications 2002;16:201-08.
36. Gerrity RG. The role of monocyte in atherogenesis, I: transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 1981;103:181-90.
37. Shelley CS, Teodoridis JM, Park H, Farokhzad OC, Bottinger EP, Arnaout MA. During differentiation of the monocytic cell line U937, Pur alpha mediates induction of the CD11c beta 2 integrih gene promoter. J Immunol 2002;168:3887-93.
38. Noti JD, Reinemann BC. The leukocyte integrin gene CD11c is transcriptionally regulated during monocyte differentiation. Mol Immunol 1995;32:361-9.
39. Mollinedo F, Gajate C, Tugores A et al. Differences in expression of transcription factor AP-1 in human promyelocytic HL-60 cells during differentiation towards macrophages versus granulocytes. Biochem J 1993;294:137-44.
40. Coccia EM, Del Russo N, Stellacci E et al. STAT1 activation during monocyte to macrophage maturation: role of adhesion molecules. Int Immunol 1999;11:1075-83.
41. WAF1/Cip1 inhibition of differentiation-induced apoptosis of monocytes. Mol Cell Biol 2001;21: 1930-41.
42. Nagase M, Ando K, Nagase T, Kamane S, Sawamura T, Fujita T. Redox-sensitive regulation of LOX-1 gene expression in vascular endothelium. Biochem Biophys Res Commun 2001;281:720-5.
43. Mietus-Snyder M, Gowri MS, Pitas RE. Class A scavenger up-regulation in smooth muscle cells by oxidized low density lipoprotein. Enhancement by calcium flux and concurrent cyclooxygenase-2 up-regulation. J Biol Chem 2000;275:17661-70.
44. Svensson L, Noren K, Wiklund O, Lindmark H, Ohlsson B, Hulten LM. Inhibitory effects of N-acetylcysteine on scavenger receptor class A expression in human macrophages. J Intern Med 2002;251:437-46.
45. Ricciarelli R, Zingg JM, Azzi A. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation 2000;102:82-7.
46. Teupser D, Thiery J, Seidel D. Alpha-tocopherol down-regulates scavenger receptor activity in macrophages. Atherosclerosis 1999;144:109-15.